Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has issued an announcement.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Allopurinol Tablets, a type 3 chemical drug. This development marks a significant step in the company’s product portfolio, enhancing its market position in the pharmaceutical industry by offering treatments for gout and other related conditions. The approval is expected to positively impact the company’s operations and provide new opportunities for growth and stakeholder engagement.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is engaged in the manufacture of various pharmaceutical products, with a market focus on treatments for conditions such as gout, leukemia, lymphoma, and recurrent calcium oxalate stones.
YTD Price Performance: -17.80%
Average Trading Volume: 13,270,514
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.38B
Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.